New checkpoint inhibitor on the block
Researchers at Austrian IMBA have identified a well-known co-factor of amino acid synthesis and monoamine neurotransmitter synthesis to play a prominent role in the development of autoimmunity and cancer.
ADVERTISEMENT
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2128 entries already.
Entries by Thomas Gabrielczyk
BIO-Europe: advanced therapies in focus
Gene and cell therapies, pediatric drugs, and formulation were just some hot topics discussed in a record number of B2B meetings at BIO-Europe in Copenhagen.
Dry AMD: Oxurion licences heparanase blockers from Beta Therapeutics
Oxurion NV and Beta Therapeutics Inc have inked an R&D agreement aimed to develop new heparanase inhibitors to treat dry AMD.
Nanobots heading to eye delivery
German researchers have developed a drug delivery nanobot that can propel through the eye.
Argenx antibody kills AML
Argenx SE announced it achieved an overall response rate of 92% in patients with AML with its anti-TNFSF7 (CD70) antibody cusatuzumab.
Sanofi and Denali Therapeutics ink €1.125bn deal in neurology/inflammation
Sanofi has acquired the global commercialisation rights for two preclinical programmes from Denali Therapeutics.
ProQR in licence deal with Ionis Pharmaceuticals
Dutch ProQR NV has licensed global commercialisation rights to IONIS-RHO-2.5Rx (QR-1123) from Ionis Pharmaceuticals, to treat autosomal dominant retinitis pigmentosa (adRP)
Fully human antibodies for advanced immunotherapies
Answering the increasing demand for novel fully human antibodies in immunotherapy, German biotech pioneer YUMAB GmbH accelerates drug discovery and development with a comprehensive and versatile technology platform.
Newron bags €40m EIB loan
The EIB has agreed to support Italian CNS drug developer Newron Pharmaceuticals with up to €40m to support the development of the company’s late-stage pipeline.
TES Pharma presents new treatment approach towards AKI and NALFD
TES Pharma has presented a novel treatment approach for acute kidney injury and non-alcoholic fatty liver disease in Nature.